BRAF and melanoma: Co-treatment of BRAF-mutant melanoma cell lines with the EP300/CREBBP inhibitor I-CBP112 decreased the sensitivity of the melanoma cells to BRAFi, increasing the number of colonies formed (Fig. 7b, c).